Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pembrolizumab · 1 trial · 1 indication
The proportion of patients that have a best overall response of complete response (CR) or partial response (PR), as assessed by RECIST 1.1.
| Arm | Type | Description |
|---|---|---|
| Pembrolizumab and Entinostat | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pembrolizumab | DRUG | 200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months |
| Entinostat | DRUG | 5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months |
Inclusion Criteria: * Age above 18 years. * Signed and dated written informed consent before the start of specific protocol procedures. * ECOG PS 0-1 * Histologically/cytologically confirmed stage IV uveal melanoma * Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI)...
Pembrolizumab is being studied for the treatment of metastatic uveal melanoma, a type of eye cancer that has spread. It is an investigational small molecule in Phase 2 clinical development. The drug is being evaluated in combination with entinostat in a completed clinical trial.
Pembrolizumab targets the PD-1 receptor, a protein on immune cells that helps regulate immune responses. By blocking PD-1, it enhances the body's immune system to attack cancer cells. This mechanism is being studied in the context of metastatic uveal melanoma.
Pembrolizumab is being developed by Syndax Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock ticker is SNDX. Syndax is conducting clinical research to evaluate the drug's safety and efficacy in patients with metastatic uveal melanoma.
Pembrolizumab is in Phase 2 clinical development for metastatic uveal melanoma. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a completed Phase 2 trial to assess its effects in this patient population.
Pembrolizumab is being studied in clinical trial NCT02697630, titled 'Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye.' This Phase 2 trial enrolled 29 participants in Sweden and has been completed. The study was not randomized or blinded and did not use a control group.